

Proposals for the classification of the myelodysplastic s

British Journal of Haematology

51, 189-99

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes.. Journal of Clinical Pathology, 1983, 36, 566-569.	1.0	41
2	Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases.. Journal of Clinical Pathology, 1983, 36, 1129-1135.	1.0	74
3	Ring sideroblasts and myelodysplastic syndromes.. Journal of Clinical Pathology, 1983, 36, 1413-1414.	1.0	2
4	Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders.. Journal of Clinical Pathology, 1983, 36, 1120-1128.	1.0	69
5	Progressive multifocal leukoencephalopathy, myelodysplastic syndrome type II and prostatic carcinoma. Postgraduate Medical Journal, 1984, 60, 157-158.	0.9	2
6	A reliable method with good cell preservation for the demonstration of peroxidase activity in human platelets and megakaryocytes. Histochemistry, 1984, 80, 79-84.	1.9	4
7	Cytochemical examinations of cultivated unclassified leukaemic cells. The Histochemical Journal, 1985, 17, 1377-1380.	0.6	3
8	Acute eosinophilic leukemia: characterization by cytochemistry, chromosomal analysis, and in vitro colony formation. Klinische Wochenschrift, 1985, 63, 133-137.	0.6	9
9	Immune abnormalities in myelodysplastic syndromes.. Journal of Clinical Pathology, 1985, 38, 908-911.	1.0	59
10	Refractory anaemia terminating in a combined lymphoproliferative and myeloproliferative disorder.. Journal of Clinical Pathology, 1985, 38, 297-300.	1.0	13
11	Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features.. Journal of Clinical Pathology, 1985, 38, 1218-1224.	1.0	98
12	Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.. Journal of Clinical Pathology, 1985, 38, 1201-1217.	1.0	99
13	Chromosomes in acute nonlymphocytic leukemia. Human Genetics, 1986, 73, 137-146.	1.8	67
14	Prognostic significance of some clinical, morphological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts. Blut, 1986, 52, 35-43.	1.2	8
15	Myelodysplastic syndromes: Their history, evolution and relation to acute myeloid leukaemia. Blut, 1986, 53, 423-436.	1.2	33
16	The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia. Blut, 1986, 52, 357-363.	1.2	17
17	Increased alpha:non-alpha globin chain synthesis ratios in myelodysplastic syndromes and myeloid leukaemia.. Journal of Clinical Pathology, 1986, 39, 1233-1235.	1.0	14
18	Primary myelodysplastic syndrome with complex chromosomal rearrangements in a patient with Klinefelter's syndrome.. Journal of Medical Genetics, 1986, 23, 183-185.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Myelodysplastic syndrome coexisting with acute lymphoblastic leukaemia.. Journal of Clinical Pathology, 1986, 39, 728-730.	1.0	16
20	Circulating micromegakaryocytes in myelodysplasia.. Journal of Clinical Pathology, 1987, 40, 1349-1352.	1.0	29
21	A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. British Journal of Cancer, 1987, 55, 523-529.	2.9	143
22	Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML). British Journal of Cancer, 1987, 56, 59-63.	2.9	21
23	The growth of myelodysplastic bone marrow in long-term cultures. British Journal of Cancer, 1987, 55, 291-293.	2.9	16
24	RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 9228-9232.	3.3	213
25	The myelodysplastic syndromes.. BMJ: British Medical Journal, 1987, 295, 227-228.	2.4	5
26	Refractory cytopenias: Clinical course according to bone marrow cytology and cellularity. Blut, 1987, 54, 153-163.	1.2	20
27	Allogeneic bone marrow transplantation as primary therapy for chronic myelomonocytic leukemia. Blut, 1987, 54, 189-192.	1.2	3
28	Leukocyte-derived inhibitory activity in patients with myelodysplastic syndrome. Blut, 1987, 55, 165-171.	1.2	5
29	In vitro exposure of leukemic cells to low concentration arabinosyl cytosine: No evidence of differentiation inducing activity. Blut, 1987, 54, 299-306.	1.2	0
30	Histopathology of bone marrow in human immunodeficiency virus infection. Virchows Archiv A, Pathological Anatomy and Histopathology, 1987, 411, 543-551.	1.4	61
31	The prognostic significance of cytological, histological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts. Blut, 1987, 54, 231-238.	1.2	7
32	Human preleukaemia: do we have a model?. British Journal of Cancer, 1987, 55, 1-5.	2.9	49
33	Detection of somatic changes in human cancer DNA by DNA fingerprint analysis. British Journal of Cancer, 1987, 55, 353-356.	2.9	131
34	Chronic myelomonocytic leukemia and primary Sjögren's syndrome. Clinical Rheumatology, 1988, 7, 110-113.	1.0	7
35	Secondary leukemia after severe aplastic anemia. Blut, 1988, 56, 79-81.	1.2	7
36	Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut, 1988, 57, 297-302.	1.2	44

#	ARTICLE	IF	CITATIONS
37	Deficiency of pluripotent hemopoietic progenitor cells in myelodysplastic syndromes. <i>Blut</i> , 1988, 57, 45-49.	1.2	22
38	Clinicopathological study of hematological disorders after Thorotrast administration in Japan. <i>Blut</i> , 1988, 56, 153-160.	1.2	9
39	Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation. <i>Blut</i> , 1988, 57, 357-360.	1.2	2
40	Sweet's syndrome and myelodysplasia. <i>Blut</i> , 1988, 56, 47-48.	1.2	14
41	Detection of chromosomal 7 loss in myelodysplasia using an extremely polymorphic DNA probe. <i>British Journal of Cancer</i> , 1988, 57, 131-134.	2.9	15
42	Diagnostic and prognostic value of DNA image cytometry in myelodysplasia.. <i>Journal of Clinical Pathology</i> , 1988, 41, 604-608.	1.0	8
43	Refractory myelodysplastic anaemias with hypocellular bone marrow.. <i>Journal of Clinical Pathology</i> , 1988, 41, 763-767.	1.0	54
45	Primary acquired sideroblastic erythropoiesis in non-anaemic and minimally anaemic subjects.. <i>Journal of Clinical Pathology</i> , 1989, 42, 56-58.	1.0	16
46	Chromosome 7 long arm deletion breakpoints in preleukemia: mapping by pulsed field gel electrophoresis. <i>Nucleic Acids Research</i> , 1989, 17, 1511-1520.	6.5	25
47	DNA index and karyotype analysis in myelodysplasia.. <i>Journal of Clinical Pathology</i> , 1989, 42, 498-501.	1.0	9
48	Acute Non-Lymphoblastic leukemias in childhood. <i>Indian Journal of Pediatrics</i> , 1989, 56, 683-692.	0.3	0
49	Bone marrow analysis of the myelodysplastic syndromes: histological and immunohistochemical features related to the evolution of overt leukemia. <i>Vigiliae Christianae</i> , 1989, 57, 47-53.	0.1	39
50	Î±-Smooth muscle actin is expressed in a subset of bone marrow stromal cells in normal and pathological conditions. <i>Vigiliae Christianae</i> , 1989, 57, 291-302.	0.1	69
51	Acute myelogenous leukaemia in children. <i>European Journal of Pediatrics</i> , 1989, 148, 382-388.	1.3	17
52	Progress in the therapy of myelodysplastic syndromes. <i>Blut</i> , 1989, 58, 265-270.	1.2	13
53	Cooperative effects of gamma-interferon and 1?, 25-dihydroxyvitamin D3 on in vitro differentiation of the blast cells of RAEB and RAEB-T. <i>Blut</i> , 1989, 58, 181-186.	1.2	7
54	Analysis of human dysplastic haematopoiesis in long-term bone marrow culture. <i>Blut</i> , 1989, 59, 442-448.	1.2	10
55	Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony-stimulating Factor. <i>Japanese Journal of Cancer Research</i> , 1989, 80, 848-854.	1.7	26

#	ARTICLE	IF	CITATIONS
56	Chronic myelomonocytic leukemia with polyneuropathy and IgA-paraprotein.. Japanese Journal of Medicine, 1989, 28, 709-716.	0.1	6
57	A case of hybrid phenotypic chronic myelomonocytic leukemia transformed from aplastic anemia.. Japanese Journal of Medicine, 1989, 28, 385-390.	0.1	2
58	The discrepancy between chemotaxis and leukotriene B4 production in a patient with chronic neutrophilic leukemia.. Japanese Journal of Medicine, 1989, 28, 717-721.	0.1	5
59	Pyogenic abscesses in the myelodysplastic syndrome.. BMJ: British Medical Journal, 1989, 299, 375-376.	2.4	21
60	The myelodysplastic syndrome.. BMJ: British Medical Journal, 1989, 299, 582-582.	2.4	60
61	Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation.. BMJ: British Medical Journal, 1990, 301, 1077-1080.	2.4	67
62	Characteristics of Granulocyte-Macrophage Colony Formation in Chronic Myelomonocytic Leukemia: A Comparative Study with Other Myelodysplastic and Myeloproliferative Disorders. Japanese Journal of Cancer Research, 1990, 81, 820-826.	1.7	7
63	Development of acute myelocytic leukemia in patients with Crohn's disease. Digestive Diseases and Sciences, 1990, 35, 1553-1556.	1.1	18
64	Acute nonlymphocytic leukemia following chemotherapy with cisplatin and etoposide for non-small-cell carcinoma of the lung: case report. Cancer Chemotherapy and Pharmacology, 1990, 26, 235-236.	1.1	10
65	Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association. Cancer Immunology, Immunotherapy, 1990, 31, 250-254.	2.0	16
66	Plasma cyclic nucleotide levels in patients with refractory anaemia with excess of blasts. Blut, 1990, 60, 177-180.	1.2	1
67	Correlations between cytogenetics and morphology in myelodysplastic syndromes. Blut, 1990, 60, 223-227.	1.2	20
68	A microcytofluorometric method for quantitative and qualitative evaluation of CFU-E and BFU-E colonies. Histochemistry, 1990, 94, 257-62.	1.9	2
69	Immunoreactive Calcitonin: A Tumor Marker for Myelogenous Leukemias. International Journal of Biological Markers, 1990, 5, 27-30.	0.7	2
70	FMS mutations in myelodysplastic, leukemic, and normal subjects.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1377-1380.	3.3	217
71	Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 6176-6180.	3.3	60
72	Ineffective hemopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation of colony-cluster formation. International Journal of Cell Cloning, 1991, 9, 521-530.	1.6	19
73	Megakaryocytopoiesis in haematological disorders: Diagnostic features of bone marrow biopsies. Virchows Archiv A, Pathological Anatomy and Histopathology, 1991, 418, 87-97.	1.4	45

#	ARTICLE	IF	CITATIONS
74	Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. <i>Annals of Hematology</i> , 1991, 63, 235-241.	0.8	56
75	Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 1991, 63, 270-275.	0.8	16
76	Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: A potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. <i>Annals of Hematology</i> , 1991, 63, 297-301.	0.8	10
77	The effect of recombinant \hat{I} -interferon on natural killer cell activity and clinical course in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 1991, 62, 225-229.	0.8	3
78	Comparative ferrokinetic study with initial and extended iron clearance models.. <i>Journal of Clinical Pathology</i> , 1991, 44, 395-399.	1.0	4
79	Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.. <i>Journal of Clinical Pathology</i> , 1991, 44, 300-305.	1.0	32
80	Globin chain synthesis in myelodysplastic syndromes.. <i>Journal of Clinical Pathology</i> , 1991, 44, 134-138.	1.0	8
81	Monocyte counting: discrepancies in results obtained with different automated instruments.. <i>Journal of Clinical Pathology</i> , 1991, 44, 224-227.	1.0	32
82	Further evidence for differential regulation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH): increased FSH and decreased LH levels in a patient with familial pure gonadal dysgenesis.. <i>Postgraduate Medical Journal</i> , 1992, 68, 925-927.	0.9	1
83	Myelodysplastic syndromes.. <i>Archives of Disease in Childhood</i> , 1992, 67, 962-966.	1.0	17
84	Oncogene expression in primary myelodysplasia: correlation with haematological, karyotypic, and clinical progression.. <i>Journal of Clinical Pathology</i> , 1992, 45, 339-343.	1.0	7
85	Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia.. <i>Journal of Clinical Pathology</i> , 1992, 45, 855-859.	1.0	17
86	Cytogenetic Analysis of Bone Marrow from Patients with Primary Myelodysplastic Syndrome. <i>Journal of International Medical Research</i> , 1992, 20, 254-266.	0.4	4
87	Clinical Use of Recombinant Human G-CSF. Aplastic Anemia (AA) and Myelodysplastic Syndromes (MDS). <i>Journal of Nutritional Science and Vitaminology</i> , 1992, 38, 349-352.	0.2	1
88	Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF). <i>Drugs</i> , 1992, 43, 516-560.	4.9	57
89	Acute Myelocytic Leukemia and Chronic Myelomonocytic Leukemia Simultaneously with Resectable Breast Cancer: A Report of two Cases. <i>Tumori</i> , 1992, 78, 356-358.	0.6	2
90	Biologic Relevance of Elevated Red Cell Adenosine Deaminase Activity in Myelodysplastic Syndromes and Paroxysmal Nocturnal Hemoglobinuria. <i>Tumori</i> , 1992, 78, 370-373.	0.6	2
91	Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy. <i>Journal of Neuro-Oncology</i> , 1992, 14, 57-62.	1.4	15

#	ARTICLE	IF	CITATIONS
92	Coincidence of primary myelodysplastic syndrome and non-Hodgkin lymphoma. <i>The Clinical Investigator</i> , 1992, 70, 1082-4.	0.6	7
93	Childhood myelodysplastic syndromes: Clinical features, cytogenetics and prognosis. <i>Indian Journal of Pediatrics</i> , 1992, 59, 443-448.	0.3	8
94	Interleukin-3 in the treatment of myelodysplastic syndromes. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 22, 125-128.	1.0	2
95	Atypical micromegakaryocytes, promegakaryoblasts and megakaryoblasts: a critical evaluation by immunohistochemistry, cytochemistry and morphometry of bone marrow trephines in chronic myeloid leukemia and myelodysplastic syndromes. <i>Vigiliae Christianae</i> , 1992, 62, 275-282.	0.1	20
96	Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment. <i>Annals of Hematology</i> , 1992, 64, 16-21.	0.8	50
97	Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow. <i>Annals of Hematology</i> , 1992, 64, 43-45.	0.8	41
98	Hypoplastic acute leukemia: description of eight cases and search for hematopoietic inhibiting activity. <i>Annals of Hematology</i> , 1992, 65, 247-252.	0.8	7
99	A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. <i>Annals of Hematology</i> , 1992, 64, 173-180.	0.8	48
100	The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study. <i>Annals of Hematology</i> , 1992, 65, 162-168.	0.8	129
101	Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). <i>Infection</i> , 1992, 20, S116-S123.	2.3	5
102	Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. <i>Annals of Hematology</i> , 1992, 65, 17-21.	0.8	19
103	Classification of myeloproliferative disorders in cats using criteria proposed by the animal leukaemia study group: A retrospective study of 181 cases (1969-1992). <i>Comparative Haematology International</i> , 1993, 3, 125-134.	0.5	33
104	Clinico-hematological profile and natural history of childhood myelodysplastic syndromes. <i>Indian Journal of Pediatrics</i> , 1993, 60, 573-581.	0.3	8
105	Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes. <i>Annals of Hematology</i> , 1993, 66, 85-91.	0.8	31
106	Biology and treatment of myelodysplastic syndromes - developments in the past decade. <i>Annals of Hematology</i> , 1993, 66, 107-115.	0.8	23
107	Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. <i>Annals of Hematology</i> , 1993, 66, 117-122.	0.8	83
108	Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. <i>Annals of Hematology</i> , 1993, 66, 175-180.	0.8	22
109	Myelodysplastic syndrome associated with relapsing polychondritis: Unusual transformation from refractory anemia to chronic myelomonocytic leukemia. <i>Annals of Hematology</i> , 1993, 67, 45-47.	0.8	20

#	ARTICLE	IF	CITATIONS
110	Myelodysplastic syndromes: Immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1993, 423, 33-38.	1.4	9
111	Detection of monosomy 7 by fluorescence in situ hybridization in acute nonlymphocytic leukemia and myelodysplastic syndrome. <i>Japanese Journal of Human Genetics</i> , 1993, 38, 257-266.	0.8	2
112	Inflammatory bowel disease and refractory anaemia (myelodysplasia).. <i>Gut</i> , 1993, 34, 1630-1631.	6.1	20
113	Sea blue histiocytosis: a common abnormality of the bone marrow in myelodysplastic syndromes.. <i>Journal of Clinical Pathology</i> , 1993, 46, 1030-1032.	1.0	30
114	Pericardial extramedullary haemopoiesis in chronic myelomonocytic leukaemia.. <i>Journal of Clinical Pathology</i> , 1993, 46, 674-675.	1.0	19
115	Lymph node disease with lymphocytic abnormal chromatin clumping in a myelodysplastic/myeloproliferative syndrome.. <i>Journal of Clinical Pathology</i> , 1993, 46, 177-179.	1.0	1
116	Detection of Monoclonal Hematopoiesis Using Restriction Fragment Length Polymorphism(RFLP) of Phosphoglycerokinase(PGK) Gene in a Patient with Hypoplastic Myelodysplastic Syndrome(MDS).. <i>Internal Medicine</i> , 1993, 32, 255-256.	0.3	2
117	Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 5484-5488.	3.3	221
118	Bone marrow lymphocyte subsets in myelodysplastic syndromes.. <i>Journal of Clinical Pathology</i> , 1994, 47, 505-507.	1.0	15
119	Reticulocyte maturity as an indicator for estimating qualitative abnormality of erythropoiesis.. <i>Journal of Clinical Pathology</i> , 1994, 47, 736-739.	1.0	40
120	Acute Sideroblastic Anemia in Active Systemic Lupus Erythematosus. <i>Lupus</i> , 1994, 3, 157-159.	0.8	14
121	Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment. <i>Annals of Hematology</i> , 1994, 68, 167-170.	0.8	5
122	Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: Evidence for a shortening of the granulocyte release time. <i>Annals of Hematology</i> , 1994, 68, 175-181.	0.8	2
123	CD 34 Immunotyping of blasts in myelodysplasia. <i>Annals of Hematology</i> , 1994, 68, 77-80.	0.8	15
124	Myelodysplastic syndromes in childhood: description of seven cases. <i>Annals of Hematology</i> , 1994, 68, 241-245.	0.8	6
125	The morphological studies on M2/t(8;21) acute nonlymphocytic leukemia. <i>Journal of Tongji Medical University</i> , 1994, 14, 38-41.	0.1	0
126	Identification and Treatment of Anaemia in Older Patients. <i>Drugs and Aging</i> , 1994, 4, 113-127.	1.3	21
127	Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. <i>British Journal of Cancer</i> , 1994, 70, 969-972.	2.9	258

#	ARTICLE	IF	CITATIONS
128	Myelodysplastic Syndromes. <i>Scottish Medical Journal</i> , 1994, 39, 5-7.	0.7	0
129	Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 10560-10564.	3.3	812
130	Refractory Anemia with an Excess of Blasts Developed into Overt Leukemia with Leukothrombocytosis.. <i>Internal Medicine</i> , 1995, 34, 28-31.	0.3	1
131	FAB classification of myelodysplastic syndromes: merits and controversies. <i>Annals of Hematology</i> , 1995, 71, 3-11.	0.8	33
132	Comparison of scoring systems in primary myelodysplastic syndromes. <i>Annals of Hematology</i> , 1995, 70, 301-308.	0.8	6
133	Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 1995, 71, 293-299.	0.8	10
134	Cytogenetic findings in 179 patients with myelodysplastic syndromes. <i>Annals of Hematology</i> , 1995, 70, 171-187.	0.8	80
135	The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995, 121, 338-342.	1.2	4
136	QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens.. <i>Journal of Clinical Pathology</i> , 1995, 48, 291-294.	1.0	29
137	Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1995, 54, 529-530.	0.5	11
138	The process of leukemogenesis.. <i>Environmental Health Perspectives</i> , 1996, 104, 1239-1246.	2.8	36
139	Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China. Benzene Study Group.. <i>Environmental Health Perspectives</i> , 1996, 104, 1353-1364.	2.8	34
141	Successful coronary artery bypass grafting for a patient with myelodysplastic syndrome: Report of a case. <i>Surgery Today</i> , 1996, 26, 740-743.	0.7	7
142	Simultaneous development of Crohn's disease and myelodysplastic syndrome progressing to acute myelocytic leukemia in a patient with a normal karyotype. <i>Journal of Gastroenterology</i> , 1996, 31, 599-602.	2.3	14
143	Behçet's disease complicated with myelodysplastic syndrome a report of two cases and review of the literature. <i>Clinical Rheumatology</i> , 1996, 15, 91-93.	1.0	31
144	Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. <i>British Journal of Cancer</i> , 1996, 74, 288-290.	2.9	64
145	Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells.. <i>Journal of Experimental Medicine</i> , 1996, 184, 1377-1384.	4.2	64
146	The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 3899-3902.	3.3	51

#	ARTICLE	IF	CITATIONS
147	Neurogenic potential of Ewing's sarcoma cells. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1997, 430, 41-46.	1.4	21
148	Autonomous proliferation and bcl-2 expression involving haematopoietic cells in patients with myelodysplastic syndrome. <i>British Journal of Cancer</i> , 1998, 78, 621-624.	2.9	15
149	Platelet dysfunction as the presenting feature of atypical myelodysplastic syndrome with monosomy 7, normal blood counts and no bleeding tendency. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1998, 15, 275-278.	1.0	2
150	Myelodysplastic Syndromes. <i>BioDrugs</i> , 1998, 10, 97-109.	2.2	4
151	Pyrexia of unknown origin, the age-old dilemma.. <i>Postgraduate Medical Journal</i> , 1998, 74, 761-763.	0.9	0
152	Pleural Effusion in Chronic Myelomonocytic Leukemia. <i>Acta Haematologica</i> , 1998, 99, 34-37.	0.7	29
153	Some Aspects of Morphological and Dysplastic Changes of the Bone Marrow in Malignant Lymphoma. <i>Acta Haematologica</i> , 1998, 100, 142-146.	0.7	3
154	Obstructive uropathy associated with myelomonocytic infiltration of the prostate. <i>Journal of Clinical Pathology</i> , 1998, 51, 340-342.	1.0	6
155	Relationship between Soluble Transferrin Receptors in Serum and Membrane-Bound Transferrin Receptors. <i>Acta Haematologica</i> , 1998, 99, 8-11.	0.7	13
157	Erythropoietin Therapy for Aplastic Anemia. <i>Internal Medicine</i> , 1998, 37, 235-235.	0.3	1
158	Diagnosis and Management of Anemia in Patients with the Myelodysplastic Syndrome. <i>Cancer Control</i> , 1998, 5, 41-45.	0.7	1
159	Apoptosis, <i>bcl-2</i> Expression and p53 Accumulation in Myelodysplastic Syndrome, Myelodysplastic-Syndrome-Derived Acute Myelogenous Leukemia and de novo Acute Myelogenous Leukemia. <i>Acta Haematologica</i> , 1999, 102, 115-123.	0.7	57
160	Flow-Cytometric Analysis of Leukocyte Alkaline Phosphatase in Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 1999, 102, 89-93.	0.7	5
161	Clinical Outcome in Three Patients with Myelodysplastic Syndrome Showing Polyclonal Hematopoiesis. <i>Acta Haematologica</i> , 1999, 101, 46-49.	0.7	5
162	Anticardiolipin Antibodies in Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 1999, 101, 161-162.	0.7	0
163	Storage of Iron in Bone Marrow Plasma Cells. <i>Acta Haematologica</i> , 1999, 101, 7-15.	0.7	23
164	Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein. <i>Oncogene</i> , 1999, 18, 3716-3724.	2.6	31
165	Leukemias and lymphomas: time trends in the UK, 1984-93. <i>Cancer Causes and Control</i> , 1999, 10, 35-42.	0.8	51

#	ARTICLE	IF	CITATIONS
167	Idiopathic myelofibrosis in a cat and in three dogs. <i>Comparative Haematology International</i> , 1999, 9, 17-24.	0.5	15
168	A strategy for erythropoietin treatment in myelodysplastic syndromes. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1999, 16, 188-190.	1.0	0
169	Micronuclei and Nuclear Abnormalities Observed in Erythroblasts in Myelodysplastic Syndromes and in de novo Acute Leukemia after Treatment. <i>Acta Haematologica</i> , 1999, 101, 32-40.	0.7	14
170	De novo Acute Myelogenous Leukemia with Trilineage Myelodysplasia Associated with t(8;21)(q22;q22).. <i>Internal Medicine</i> , 1999, 38, 607-611.	0.3	3
172	Fusion of the Nucleoporin Gene, NUP98, and the Putative RNA Helicase Gene, DDX10, by Inversion 11 (p15q22) Chromosome Translocation in a Patient with Etoposide-related Myelodysplastic Syndrome.. <i>Internal Medicine</i> , 2000, 39, 412-415.	0.3	22
174	Chronic Myelomonocytic Leukemia in a Cat.. <i>Journal of Veterinary Medical Science</i> , 2000, 62, 195-197.	0.3	12
175	Clonality Analysis of Various Hematopoietic Disorders in Cats Naturally Infected with Feline Leukemia Virus.. <i>Journal of Veterinary Medical Science</i> , 2000, 62, 1059-1065.	0.3	22
176	Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. <i>British Journal of Cancer</i> , 2000, 83, 91-94.	2.9	49
177	Myelodysplastic syndromes. <i>Current Treatment Options in Oncology</i> , 2000, 1, 63-69.	1.3	9
178	Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia. <i>Current Oncology Reports</i> , 2000, 2, 140-143.	1.8	7
179	Prevalence and Survival of Myelodysplastic Syndrome of the Refractory Anemia Type in Hospitalized Cognitively Different Geriatric Patients. <i>Gerontology</i> , 2000, 46, 323-327.	1.4	15
180	Comparative Genomic Hybridization Study of de novo Myeloid Neoplasia. <i>Acta Haematologica</i> , 2000, 104, 25-30.	0.7	11
181	Increased Prevalence of GSTM₁ Null Genotype in Patients with Myelodysplastic Syndrome: A Case-Control Study. <i>Acta Haematologica</i> , 2000, 104, 169-173.	0.7	17
182	Myelodysplastic Syndromes in the Elderly. <i>Cancer Control</i> , 2001, 8, 79-102.	0.7	13
183	Myelodysplastic Syndrome Accompanied by Addison's Disease and Multiple Autoimmune Phenomena: Steroid Therapy Resolved Cytopenias and All Immune Disorders.. <i>Internal Medicine</i> , 2001, 40, 1041-1044.	0.3	13
184	Immune Pathology of Myelodysplastic Syndromes. <i>Internal Medicine</i> , 2001, 40, 985-986.	0.3	0
185	Treatment of Myelodysplastic Syndrome With Low-Dose Human Granulocyte Colony-Stimulating Factor: A Multicenter Study. <i>International Journal of Hematology</i> , 2001, 74, 144-146.	0.7	7
186	Proliferative Capacity of Single Isolated CD34+ Hematopoietic Stem/Progenitor Cells in Paroxysmal Nocturnal Hemoglobinuria. <i>International Journal of Hematology</i> , 2001, 74, 42-52.	0.7	1

#	ARTICLE	IF	CITATIONS
187	Epidemiological Features of Myelodysplastic Syndromes: Results From Regional Cancer Surveys and Hospital-Based Statistics. <i>International Journal of Hematology</i> , 2001, 73, 405-410.	0.7	80
188	Bone Marrow Colony-Forming Unit Assay in Cats With Naturally Occurring Myelodysplastic Syndromes. <i>International Journal of Hematology</i> , 2001, 73, 453-456.	0.7	8
189	Reduced CD43 Expression on the Neutrophils of MDS Patients Correlates With an Activated Phenotype of These Cells. <i>International Journal of Hematology</i> , 2001, 73, 483-491.	0.7	16
190	Morphological diagnoses of the Japan Adult Leukemia Study Group acute myeloid leukemia protocols: Central review. <i>International Journal of Hematology</i> , 2001, 73, 93-99.	0.7	21
191	Tyrosine phosphorylation of proteins in primary human myeloid leukemic cells stimulated by macrophage colony-stimulating factor: Analysis by disease type and comparison with normal human hematopoietic cells. <i>International Journal of Hematology</i> , 2001, 73, 100-107.	0.7	1
192	Myelodysplasia-Like Syndrome and End-Stage Liver Disease. <i>Acta Haematologica</i> , 2001, 105, 100-102.	0.7	1
193	Unusual Myelodysplastic Syndrome with the Initial Presentation Mimicking Idiopathic Thrombocytopenic Purpura. <i>Acta Haematologica</i> , 2002, 108, 139-143.	0.7	25
194	Circulating Levels of Thrombopoietic and Inflammatory Cytokines in Patients with Acute Myeloblastic Leukemia and Myelodysplastic Syndrome. <i>Oncology</i> , 2002, 63, 64-69.	0.9	71
195	Myelodysplastic Syndrome Following Therapy for Brain Tumor. Two Case Reports.. <i>Neurologia Medico-Chirurgica</i> , 2002, 42, 170-174.	1.0	3
196	Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Expressing p190BCR-ABL.. <i>Internal Medicine</i> , 2002, 41, 1183-1187.	0.3	36
197	Myelodysplastic Syndrome. <i>American Journal of Cancer</i> , 2002, 1, 301-311.	0.4	1
198	Two Independent Clones in Myelodysplastic Syndrome Following Treatment of Acute Myeloid Leukemia. <i>International Journal of Hematology</i> , 2002, 75, 182-186.	0.7	9
199	Biological Significance of Proliferation, Apoptosis, Cytokines, and Monocyte/Macrophage Cells in Bone Marrow Biopsies of 145 Patients With Myelodysplastic Syndrome. <i>International Journal of Hematology</i> , 2002, 75, 289-297.	0.7	77
200	Reversible Acceleration of Disease Progression Following Cyclosporin A Treatment in a Patient With Myelodysplastic Syndrome. <i>International Journal of Hematology</i> , 2002, 75, 302-304.	0.7	5
201	Pure Red Cell Aplasia Developing into Myeloproliferation with Myelodysplasia and Subsequent Leukemia after Cyclosporin A Therapy. <i>International Journal of Hematology</i> , 2002, 75, 514-518.	0.7	7
202	Histologic Verification of Leukemia, Myelodysplasia, and Multiple Myeloma Diagnoses in Patients in Ukraine, 1987-1998. <i>International Journal of Hematology</i> , 2002, 76, 55-60.	0.7	12
203	Platelet Dysfunction in Myelodysplastic Syndromes: A Clinicopathological Study. <i>International Journal of Hematology</i> , 2002, 76, 272-278.	0.7	42
204	Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis. <i>International Journal of Hematology</i> , 2002, 76, 29-34.	0.7	14

#	ARTICLE	IF	CITATIONS
205	Important features of myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2002, 76, 222-227.	0.7	10
206	The Myelodysplastic Syndromes: Morphology, risk assessment, and clinical management (2002). <i>International Journal of Hematology</i> , 2002, 76, 228-238.	0.7	37
207	Chronic myelomonocytic leukemia. <i>Current Treatment Options in Oncology</i> , 2002, 3, 221-223.	1.3	55
208	Early diagnosis of myelodysplastic syndromes using clonal analyses. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2002, 14, 225-229.	0.7	1
209	Risk factors for myelodysplastic syndromes: a case-control study in Greece. <i>Cancer Causes and Control</i> , 2002, 13, 603-608.	0.8	55
210	Biological and Clinical Significance of Clonogenic Assays in Patients with Myelodysplastic Syndromes. <i>Medical Oncology</i> , 2002, 19, 249-260.	1.2	14
211	Oxidative Stress and the Myelodysplastic Syndromes. <i>International Journal of Hematology</i> , 2003, 77, 342-350.	0.7	86
212	Successful aortic valve replacement in severe pancytopenia related to myelodysplastic syndrome. <i>General Thoracic and Cardiovascular Surgery</i> , 2003, 51, 77-80.	0.4	7
213	Successful replacement of aortic root with valve-sparing technique and proximal arch in a patient with myelodysplastic syndrome. <i>General Thoracic and Cardiovascular Surgery</i> , 2003, 51, 322-325.	0.4	5
214	Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 515-536.	1.0	4
215	Diagnostische und prognostische Bedeutung von koloniebildenden hämatopoetischen Vorläuferzellen in myeloischen Systemerkrankungen. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 537-546.	1.0	13
216	Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2003, 82, 271-277.	0.8	13
217	Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. <i>Annals of Hematology</i> , 2003, 82, 336-342.	0.8	97
218	Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003, 129, 485-491.	1.2	14
219	Apoptotic rate in patients with myelodysplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines. <i>Journal of Cellular and Molecular Medicine</i> , 2003, 7, 313-321.	1.6	4
220	Myelodysplasia: Differentiating Neoplastic from Nonneoplastic Syndromes of Ineffective Hematopoiesis in Dogs. <i>Toxicologic Pathology</i> , 2003, 31, 44-48.	0.9	13
222	Classification, Treatment Goals, and Management Principles for Myelodysplastic Syndromes. <i>Cancer Control</i> , 2004, 11, 3-6.	0.7	7
223	Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 578-582.	0.5	43

#	ARTICLE	IF	CITATIONS
224	FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia. <i>Acta Haematologica</i> , 2004, 112, 68-78.	0.7	67
225	Strategies for the Laboratory Diagnosis of Some Common Causes of Anaemia in Elderly Patients. <i>Gerontology</i> , 2004, 50, 49-56.	1.4	32
226	Models of granulocyte DNA structure are highly predictive of myelodysplastic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5008-5011.	3.3	15
227	Myelofibrosis in Primary Myelodysplastic Syndromes: Clinical and Biological Significance. <i>Medical Oncology</i> , 2004, 21, 325-332.	1.2	22
228	Long-Term Survivors in Myelodysplastic Syndromes: Clinical and Biological Characteristics. <i>Medical Oncology</i> , 2004, 21, 333-338.	1.2	4
229	Possibility of the Diagnosis of Subacute Myeloid Leukemia for a Group of Patients with Trisomy 8: A Report of 34 Cases. <i>International Journal of Hematology</i> , 2004, 80, 159-163.	0.7	0
230	Simultaneous Demonstration of Clonal Chromosome Abnormalities and Apoptosis in Individual Marrow Cells in Myelodysplastic Syndrome. <i>International Journal of Hematology</i> , 2004, 80, 140-145.	0.7	38
231	Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. <i>Journal of Molecular Histology</i> , 2004, 35, 857-863.	1.0	14
232	The effect of LIGHT in inducing maturation of monocyte-derived dendritic cells from MDS patients. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 681-9.	2.0	16
233	High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival. <i>Annals of Hematology</i> , 2004, 83, 9-13.	0.8	22
234	Absence of MLL gene rearrangement in de novo myelodysplastic syndromes (MDS). <i>Annals of Hematology</i> , 2004, 83, 170-175.	0.8	7
235	Hypocellular Myelodysplastic Syndromes: Clinical and Biological Significance. <i>Medical Oncology</i> , 2005, 22, 169-176.	1.2	29
236	Spontaneous Remission in Adults with Primary Myelodysplastic Syndromes: Incidence and Characteristics of Patients. <i>Medical Oncology</i> , 2005, 22, 407-410.	1.2	9
237	Serial Morphologic Observation of Bone Marrow in Aplastic Anemia in Children. <i>International Journal of Hematology</i> , 2005, 81, 400-404.	0.7	1
238	Unrelated Cord Blood Transplantation after Myeloablative Conditioning for Adult Patients with Refractory Anemia. <i>International Journal of Hematology</i> , 2005, 81, 424-427.	0.7	6
239	Myelodysplastic Syndrome. <i>International Journal of Hematology</i> , 2005, 82, 412-416.	0.7	12
240	Refractory Thrombocytopenia, an Unusual Myelodysplastic Syndrome with an Initial Presentation Mimicking Idiopathic Thrombocytopenic Purpura. <i>International Journal of Hematology</i> , 2005, 81, 142-147.	0.7	11
241	Comparison of 2 Preparative Regimens for Stem Cell Transplantation from HLA-Matched Sibling Donors in Patients with Advanced Myelodysplastic Syndrome. <i>International Journal of Hematology</i> , 2005, 82, 66-71.	0.7	4

#	ARTICLE	IF	CITATIONS
242	Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. <i>Bone Marrow Transplantation</i> , 2005, 35, 455-461.	1.3	19
243	Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. <i>Oncogene</i> , 2005, 24, 2441-2448.	2.6	71
244	Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 953-970.	2.0	35
245	Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes? a comparative analysis of results with reports from Asia. <i>Annals of Hematology</i> , 2005, 84, 298-303.	0.8	11
246	Clinical experience with decitabine in North American patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2005, 84, 18-24.	0.8	8
247	The hematopathological basis for studying effects of the demethylating agent 5-aza-2- β -deoxycytidine (decitabine) in myelodysplasia. <i>Annals of Hematology</i> , 2005, 84, 67-79.	0.8	6
248	Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol- α : a phase II study. <i>Annals of Hematology</i> , 2005, 84, 389-394.	0.8	26
249	Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). <i>Annals of Hematology</i> , 2005, 84, 429-433.	0.8	52
250	Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. <i>Annals of Hematology</i> , 2005, 84, 569-571.	0.8	71
251	Ocular Complications in Myelodysplastic Syndromes as Preleukemic Disorders. <i>Japanese Journal of Ophthalmology</i> , 2005, 49, 377-383.	0.9	18
252	Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. <i>Nature Clinical Practice Oncology</i> , 2005, 2, S12-S23.	4.3	68
253	Autoimmune Disorders in Two Patients with Myelodysplastic Syndrome and 5q Deletion. <i>Acta Haematologica</i> , 2005, 113, 146-149.	0.7	17
254	Azacitidine. <i>Drugs</i> , 2005, 65, 1781-1789.	4.9	10
255	The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. <i>Blood</i> , 2005, 106, 1207-1209.	0.6	447
256	5-Azacytidine and Decitabine Monotherapies of Myelodysplastic Disorders. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1700-1709.	0.9	32
257	The Hematologic Response to Anti-apoptotic Cytokine Therapy: Results of Pentoxifylline, Ciprofloxacin, and Dexamethasone Treatment for Patients with Myelodysplastic Syndrome. <i>Journal of Korean Medical Science</i> , 2006, 21, 40.	1.1	2
258	Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. <i>Blood</i> , 2006, 108, 2632-2641.	0.6	84
259	Successful Reduced-Intensity Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome with Severe Coronary Artery Disease. <i>International Journal of Hematology</i> , 2006, 83, 156-158.	0.7	1

#	ARTICLE	IF	CITATIONS
260	Alemtuzumab Therapy for Severe Autoimmune Hemolysis in a Patient with B-Cell Chronic Lymphocytic Leukemia. <i>Medical Oncology</i> , 2006, 23, 137-140.	1.2	13
261	Immunologic Abnormalities in Myelodysplastic Syndromes: Clinical Features and Characteristics of the Lymphoid Population. <i>Medical Oncology</i> , 2006, 23, 385-392.	1.2	41
262	Alterations of CD43 expression in transfusion-dependent myelodysplastic syndromes. <i>Annals of Hematology</i> , 2006, 85, 281-284.	0.8	3
263	Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. <i>Annals of Hematology</i> , 2006, 85, 502-513.	0.8	35
264	A case-control study of myelodysplastic syndromes in Belgrade (Serbia Montenegro). <i>Annals of Hematology</i> , 2006, 85, 514-519.	0.8	27
265	Causes of incidental neutropenia in adulthood. <i>Annals of Hematology</i> , 2006, 85, 705-709.	0.8	35
266	Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. <i>Annals of Hematology</i> , 2006, 86, 133-137.	0.8	30
267	Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 9-15.	1.2	0
268	Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 16-19.	1.2	3
269	Farnesyltransferase inhibitors in myelodysplastic syndrome. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 20-24.	1.2	6
270	New agents in myelodysplastic syndromes. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 25-33.	1.2	2
271	Arsenic trioxide as a treatment for myelodysplastic syndrome. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 34-38.	1.2	4
272	Fluorescence in situ Hybridization Reveals Closely Correlated Results in Cytological and Histological Specimens of Hematological Neoplasias Compared to Conventional Cytogenetics. <i>Pathobiology</i> , 2006, 73, 271-279.	1.9	4
273	From the cover: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1307-1312.	3.3	91
274	Going from genes to proteins in myelodysplastic syndromes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1109-1110.	3.3	1
275	Circulating Adiponectin and Leptin in Relation to Myelodysplastic Syndrome: A Case-Control Study. <i>Oncology</i> , 2007, 73, 26-32.	0.9	45
276	Refractory Anaemia with Excess of Blasts in Transformation Re-Evaluated with the WHO Criteria: Identification of Subgroups with Different Survival. <i>Acta Haematologica</i> , 2007, 117, 221-225.	0.7	3
278	A Dog with Myelodysplastic Syndrome: Chronic Myelomonocytic Leukemia. <i>Journal of Veterinary Medical Science</i> , 2007, 69, 665-668.	0.3	9

#	ARTICLE	IF	CITATIONS
279	Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. <i>Blood</i> , 2007, 110, 1379-1387.	0.6	144
280	Chemiluminescent determination of leukocyte alkaline phosphatase: an advantageous alternative to the cytochemical assay. <i>Journal of Clinical Laboratory Analysis</i> , 2007, 21, 91-96.	0.9	5
281	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. <i>Cancer</i> , 2007, 109, 1133-1137.	2.0	182
282	Myelodysplastic syndromes: the complexity of stem-cell diseases. <i>Nature Reviews Cancer</i> , 2007, 7, 118-129.	12.8	311
283	Enhanced growth of myelodysplastic colonies in hypoxic conditions. <i>Experimental Hematology</i> , 2007, 35, 21-31.	0.2	27
284	High-Resolution Genomic Arrays Facilitate Detection of Novel Cryptic Chromosomal Lesions in Myelodysplastic Syndromes. <i>Experimental Hematology</i> , 2007, 35, 240-251.	0.2	29
285	Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. <i>Experimental Hematology</i> , 2007, 35, 1739-1746.	0.2	109
286	Immunomodulatory Therapy for Myelodysplastic Syndromes. <i>International Journal of Hematology</i> , 2007, 86, 301-305.	0.7	11
287	Evolving New Treatment for Myelodysplastic Syndromes. <i>International Journal of Hematology</i> , 2007, 86, 297-300.	0.7	1
288	A Prospective Study of Cyclosporine A Treatment of Patients with Low-Risk Myelodysplastic Syndrome: Presence of CD55-CD59- Blood Cells Predicts Platelet Response. <i>International Journal of Hematology</i> , 2007, 86, 150-157.	0.7	20
289	High Incidence of Morphological Myelodysplasia and Apoptotic Bone Marrow Cells in Behçet's Disease. <i>Journal of Clinical Immunology</i> , 2007, 27, 145-151.	2.0	10
290	Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia. <i>Current Treatment Options in Oncology</i> , 2007, 8, 117-128.	1.3	25
291	Iron overload in patients with myelodysplastic syndromes. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 13-21.	1.2	6
292	The cell growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS. <i>Medical Oncology</i> , 2007, 24, 419-424.	1.2	5
293	Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?. <i>Cancer Causes and Control</i> , 2008, 19, 371-378.	0.8	18
294	Concurrent Inflammatory Bowel Disease and Myelodysplastic Syndrome: Report of Nine New Cases and a Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1929-1932.	1.1	14
295	Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. <i>Annals of Hematology</i> , 2008, 87, 537-544.	0.8	36
296	Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. <i>Annals of Hematology</i> , 2008, 87, 691-699.	0.8	88

#	ARTICLE	IF	CITATIONS
297	Lenalidomide in myelodysplastic syndromes: Where do we go from here?. Current Hematologic Malignancy Reports, 2008, 3, 5-9.	1.2	0
298	Prognosis in myelodysplastic syndromes: Are the new classifications useful?. Current Hematologic Malignancy Reports, 2008, 3, 19-22.	1.2	0
299	Diagnosis and management of chronic myelomonocytic leukemia. Current Hematologic Malignancy Reports, 2008, 3, 31-36.	1.2	4
300	Myelodysplastic syndrome: An update on diagnosis and therapy. Current Oncology Reports, 2008, 10, 372-378.	1.8	6
301	Hemogram and bone marrow morphology in children with chronic aplastic anemia and myelodysplastic syndrome. World Journal of Pediatrics, 2008, 4, 36-40.	0.8	3
302	Clonality investigation of morphologically dysplastic hematopoietic cells in myelodysplastic syndrome marrows. International Journal of Hematology, 2008, 87, 176-183.	0.7	3
303	Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. International Journal of Hematology, 2008, 88, 24-29.	0.7	105
304	Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children. International Journal of Hematology, 2008, 88, 524-529.	0.7	8
305	An analysis of complex chromosomal aberrations in seven cases of myelodysplastic syndromes by M-FISH and whole chromosome painting. International Journal of Hematology, 2008, 88, 369-373.	0.7	8
307	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer, 2008, 113, 1933-1952.	2.0	84
308	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer, 2008, 113, 1351-1361.	2.0	458
309	Haploinsufficiency of <i>RPS14</i> in 5q ⁺ syndrome is associated with deregulation of ribosomal- and translation-related genes. British Journal of Haematology, 2008, 142, 57-64.	1.2	91
310	Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. British Journal of Haematology, 2008, 142, 379-393.	1.2	74
311	Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on respiratory burst activity of neutrophils in patients with myelodysplastic syndromes. Clinical and Experimental Immunology, 2008, 91, 308-313.	1.1	17
312	Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. European Journal of Clinical Investigation, 2008, 38, 143-149.	1.7	54
313	Role of epigenetic therapy in myelodysplastic syndrome. Expert Review of Hematology, 2008, 1, 161-174.	1.0	0
314	Identification and functional characterization of novel telomerase variant alleles in Japanese patients with bone-marrow failure syndromes. Blood Cells, Molecules, and Diseases, 2008, 40, 185-191.	0.6	24
315	Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys. Journal of the National Cancer Institute, 2008, 100, 1542-1551.	3.0	243

#	ARTICLE	IF	CITATIONS
316	Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2865-2870.	3.3	122
317	Solving the Mystery of Myelodysplasia. PLoS Medicine, 2008, 5, e40.	3.9	5
318	Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood, 2008, 112, 2681-2686.	0.6	107
319	A Case of Sweet's Syndrome with Extensive Necrosis and Ulcers Accompanied by Myelodysplastic Syndrome. Journal of Nippon Medical School, 2008, 75, 162-165.	0.3	8
320	Defective ribosome biogenesis in myelodysplastic syndromes. Haematologica, 2009, 94, 1336-1338.	1.7	4
321	Management of Multiple Myeloma and Myelodysplastic Syndrome: Focus on Lenalidomide. Clinical Medicine Therapeutics, 2009, 1, CMT.S2295.	0.1	0
322	G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica, 2009, 94, 1449-1452.	1.7	36
323	Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16811-16816.	3.3	98
324	Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort. American Journal of Epidemiology, 2009, 169, 1492-1499.	1.6	68
325	Ectopic expression of C/EBP α and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia. Haematologica, 2009, 94, 1075-1084.	1.7	8
326	A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. European Journal of Haematology, 1996, 56, 7-11.	1.1	21
327	Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan. Cancer, 2009, 115, 84-93.	2.0	6
328	The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities. Cancer, 2009, 115, 5202-5209.	2.0	40
329	Therapy related CMML: a case report and review of the literature. International Journal of Hematology, 2009, 89, 699-703.	0.7	17
330	Myelodysplastic syndrome: An update on diagnosis and therapy. Current Hematologic Malignancy Reports, 2009, 4, 10-16.	1.2	1
331	Analysis of WHO-based Prognostic Scoring System (WPSS) of myelodysplastic syndrome and its comparison with international prognostic scoring system (IPSS) in 100 Chinese patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2009, 21, 50-55.	0.7	2
332	Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS). Memo - Magazine of European Medical Oncology, 2009, 2, 13-17.	0.3	0
334	Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia, 2009, 23, 1605-1613.	3.3	85

#	ARTICLE	IF	CITATIONS
335	Preclinical and clinical experience with dasatinib in philadelphia chromosome-negative leukemias and myeloid disorders. <i>Leukemia Research</i> , 2009, 33, 617-623.	0.4	8
336	Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, 1594-1598.	0.4	83
337	Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2009, 113, 6403-6410.	0.6	351
338	Azacitidine. <i>Drugs</i> , 2009, 69, 2501-2518.	4.9	21
339	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. <i>Lancet Oncology</i> , The, 2009, 10, 223-232.	5.1	2,404
340	Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). <i>Blood</i> , 2009, 114, 2393-2400.	0.6	183
341	Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Blood</i> , 2009, 114, 3899-3908.	0.6	119
342	Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. <i>Blood</i> , 2009, 114, 2575-2580.	0.6	13
343	Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. <i>Haematologica</i> , 2010, 95, 1754-1761.	1.7	73
344	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. <i>Haematologica</i> , 2010, 95, 892-899.	1.7	18
345	Demethylating Agents in the Treatment of Cancer. <i>Pharmaceuticals</i> , 2010, 3, 2022-2044.	1.7	50
346	Expression analysis of proteins involved in the non homologous end joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes. <i>Annals of Hematology</i> , 2010, 89, 233-239.	0.8	11
347	Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. <i>Annals of Hematology</i> , 2010, 89, 365-374.	0.8	74
348	Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study. <i>Annals of Hematology</i> , 2010, 89, 535-544.	0.8	17
349	Myelodysplastic syndromes: an update on molecular pathology. <i>Clinical and Translational Oncology</i> , 2010, 12, 652-661.	1.2	16
350	Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. <i>International Journal of Hematology</i> , 2010, 91, 97-103.	0.7	16
351	Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes. <i>International Journal of Hematology</i> , 2010, 91, 602-610.	0.7	9
352	Cause of death in patients with lower-risk myelodysplastic syndrome. <i>Cancer</i> , 2010, 116, 2174-2179.	2.0	142

#	ARTICLE	IF	CITATIONS
353	Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. <i>Molecular Cytogenetics</i> , 2010, 3, 23.	0.4	28
354	Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors – International Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues. <i>Journal of Blood Medicine</i> , 2010, 1, 171.	0.7	25
355	ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010019.	0.5	1
356	Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome. <i>Advances in Hematology</i> , 2010, 2010, 1-5.	0.6	41
357	Immune Dysregulation in Myelodysplastic Syndrome. <i>Hematology Reports</i> , 2010, 2, e1.	0.3	17
358	Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2010, 28, 2253-2258.	0.8	131
359	Current and Future Management Options for Myelodysplastic Syndromes. <i>Drugs</i> , 2010, 70, 1381-1394.	4.9	10
360	Myelodysplastic Syndromes: From Neglect to Prominence. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S28-S29.	2.0	0
361	GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 111.	3.5	10
362	Cytogenetic risk stratification in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2011, 96, 375-383.	1.7	226
363	Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. <i>Haematologica</i> , 2011, 96, 441-449.	1.7	220
364	Myelodysplastic Syndromes. <i>Clinics in Laboratory Medicine</i> , 2011, 31, 763-784.	0.7	12
365	Myelodysplastic Syndrome of del 20q with Plasma Cell Dysplasia. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2011, 51, 141-145.	0.3	2
366	Myelodysplastic Syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 30-56.	2.3	177
367	Mitral Valve Repair in a Patient with Myelodysplastic Syndrome. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2011, 17, 614-617.	0.3	4
368	Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). <i>Haematologica</i> , 2011, 96, 1433-1440.	1.7	247
369	T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. <i>Blood</i> , 2011, 117, 2691-2699.	0.6	77
370	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. <i>Blood</i> , 2011, 118, 4690-4693.	0.6	88

#	ARTICLE	IF	CITATIONS
371	A Case of Chronic Myelomonocytic Leukemia Who Developed Pericardial Effusion during Stably Controlled Leukocytosis. <i>Internal Medicine</i> , 2011, 50, 1737-1740.	0.3	1
372	Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , 2011, 96, 349-352.	1.7	20
373	Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes. <i>Diagnostic Pathology</i> , 2011, 6, 93.	0.9	11
374	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. <i>Blood</i> , 2011, 118, 3932-3941.	0.6	290
375	Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. <i>Cancer Causes and Control</i> , 2011, 22, 623-629.	0.8	10
376	Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. <i>Annals of Hematology</i> , 2011, 90, 655-666.	0.8	12
377	Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2011, 94, 169-177.	0.7	15
378	Azacitidine for the treatment of myelodysplastic syndromes in the elderly. <i>Advances in Therapy</i> , 2011, 28, 10-15.	1.3	1
379	Treatment of myelodysplastic syndromes in elderly patients. <i>Advances in Therapy</i> , 2011, 28, 1-9.	1.3	3
380	Azacitidine for the treatment of patients with acute myeloid leukemia with 20%–30% blasts and multilineage dysplasia. <i>Advances in Therapy</i> , 2011, 28, 1-9.	1.3	8
381	Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. <i>Clinical Epigenetics</i> , 2011, 2, 389-399.	1.8	42
382	Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder (qinghuang powder). <i>Chinese Journal of Integrative Medicine</i> , 2011, 17, 834-839.	0.7	20
383	The Search for Better Prognostic Models in Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 13-21.	1.2	11
384	Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 5-12.	1.2	3
385	Management of Lower-Risk Myelodysplastic Syndromes: The Art and Evidence. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 145-153.	1.2	22
386	Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes. <i>BMC Medical Genomics</i> , 2011, 4, 19.	0.7	41
387	Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. <i>Cancer</i> , 2011, 117, 2697-2702.	2.0	169
388	Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. <i>Journal of Clinical Oncology</i> , 2011, 29, 1963-1970.	0.8	139

#	ARTICLE	IF	CITATIONS
389	Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2011, 29, 2240-2246.	0.8	131
390	Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: "To Be or Not to Be Acetylated". <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-15.	3.0	18
391	Review of Stem-Cell Transplantation for Myelodysplastic Syndromes in Older Patients in the Context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome Emanating From the Centers for Medicare and Medicaid Services. <i>Journal of Clinical Oncology</i> , 2011, 29, 566-572.	0.8	31
392	Myelodysplastic Syndrome and Benzene Exposure Among Petroleum Workers: An International Pooled Analysis. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1724-1737.	3.0	152
395	Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy. <i>Skeletal Radiology</i> , 2012, 41, 611-614.	1.2	12
396	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. <i>Journal of Clinical Oncology</i> , 2012, 30, 820-829.	0.8	584
397	Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. <i>Leukemia</i> , 2012, 26, 2447-2454.	3.3	98
398	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 2454-2465.	0.6	2,458
399	Myelodysplastic Syndromes: Challenges to Improving Patient and Caregiver Satisfaction. <i>American Journal of Medicine</i> , 2012, 125, S26-S30.	0.6	8
400	Azacitidine. <i>Drugs</i> , 2012, 72, 1111-1136.	4.9	40
401	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 373-381.	1.3	6
402	Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 310-320.	1.2	86
403	The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. <i>Annals of Hematology</i> , 2012, 91, 1333-1343.	0.8	41
404	Predicting survival of patients with hypocellular myelodysplastic syndrome. <i>Cancer</i> , 2012, 118, 4462-4470.	2.0	38
405	Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971. <i>Cancer</i> , 2012, 118, 4806-4814.	2.0	72
406	Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2012, 95, 232-238.	0.7	31
407	Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island. <i>International Journal of Hematology</i> , 2012, 95, 420-427.	0.7	1
408	Angiogenesis and Survival in Patients with Myelodysplastic Syndrome. <i>Pathology and Oncology Research</i> , 2012, 18, 681-690.	0.9	18

#	ARTICLE	IF	CITATIONS
409	Characteristics of MDS patients seen at private practices differ significantly from those treated at university hospitals in Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 953-957.	1.2	2
410	Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. <i>Annals of Hematology</i> , 2012, 91, 39-46.	0.8	12
411	Microscopic examination of bone marrow aspirates in malignant disorders of haematopoiesis—a comparison of two slide preparation techniques. <i>Annals of Hematology</i> , 2012, 91, 497-505.	0.8	5
412	Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. <i>Journal of Hematology and Oncology</i> , 2013, 6, 29.	6.9	49
413	Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. <i>Annals of Hematology</i> , 2013, 92, 19-24.	0.8	65
414	Border between aplastic anemia and myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2013, 97, 558-563.	0.7	13
415	Myelodysplastic syndromes: What do hospitalists need to know?. <i>Journal of Hospital Medicine</i> , 2013, 8, 351-357.	0.7	21
416	High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. <i>Annals of Hematology</i> , 2013, 92, 621-631.	0.8	40
417	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
418	Therapeutic effects of thalidomide in hematologic disorders: a review. <i>Frontiers of Medicine</i> , 2013, 7, 290-300.	1.5	10
419	Current therapy of myelodysplastic syndromes. <i>Blood Reviews</i> , 2013, 27, 243-259.	2.8	75
420	Standardizing the Initial Evaluation for Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 361-369.	1.2	4
421	Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2013, 98, 687-693.	0.7	4
422	There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 351-360.	1.2	37
423	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , 2013, 122, 2943-2964.	0.6	567
424	The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?. <i>Expert Review of Hematology</i> , 2013, 6, 59-68.	1.0	16
425	Myelodysplasia: New Approaches. <i>Current Treatment Options in Oncology</i> , 2013, 14, 156-169.	1.3	4
427	Surgical treatment for esophageal cancer patients with myelodysplastic syndrome. <i>Esophagus</i> , 2013, 10, 149-152.	1.0	1

#	ARTICLE	IF	CITATIONS
428	Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. <i>Haematologica</i> , 2013, 98, 201-207.	1.7	34
429	TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013032.	0.5	3
430	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2662-2670.	0.8	265
431	Efficacy of Oral Cytarabine Ocfosfate and Etoposide in the Treatment of Elderly Patients with Higher-Risk Myelodysplastic Syndromes Compared to That in Elderly Acute Myeloid Leukemia Patients. <i>Chemotherapy</i> , 2013, 59, 152-158.	0.8	5
432	Prognostic impact of <i>RAS</i> mutations in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 365-369.	2.0	30
433	Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. <i>Haematologica</i> , 2013, 98, 1344-1352.	1.7	35
434	Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 592-598.	0.8	94
435	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013, 122, 1974-1982.	0.6	92
436	Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary?. <i>Haematologica</i> , 2013, 98, 490-491.	1.7	13
437	Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. <i>Haematologica</i> , 2013, 98, 568-575.	1.7	63
438	Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. <i>Haematologica</i> , 2013, 98, 584-590.	1.7	13
439	Myelodysplastic Syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 838-874.	2.3	181
440	A case of myelodysplastic syndrome with marked eosinophilia showing favorable prognosis. <i>Blood Research</i> , 2013, 48, 222.	0.5	1
441	Distinct Clinical and Experimental Characteristics in the Patients Younger than 60 Years Old with Myelodysplastic Syndromes. <i>PLoS ONE</i> , 2013, 8, e57392.	1.1	10
442	A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes. <i>PLoS ONE</i> , 2013, 8, e67537.	1.1	31
443	Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores. <i>PLoS ONE</i> , 2013, 8, e81048.	1.1	22
444	Acute Myelogenous Leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: Retrospective Analysis of Molecular Genetic Evaluation. <i>Baylor University Medical Center Proceedings</i> , 2014, 27, 299-304.	0.2	1
445	Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 421-431.	1.2	3

#	ARTICLE	IF	CITATIONS
446	Translational hematology. Wiener Medizinische Wochenschrift, 2014, 164, 487-496.	0.5	0
447	Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan. International Journal of Hematology, 2014, 100, 478-484.	0.7	10
448	Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. Journal of Hematology and Oncology, 2014, 7, 74.	6.9	90
449	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia, 2014, 28, 621-628.	3.3	80
450	Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). Blood Cancer Journal, 2014, 4, e242-e242.	2.8	24
451	Cytogenetic as an Important Tool for Diagnosis and Prognosis for Patients with Hypocellular Primary Myelodysplastic Syndrome. BioMed Research International, 2014, 2014, 1-10.	0.9	10
452	Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. Journal of Blood Medicine, 2014, 6, 1.	0.7	14
453	<i>BRAF</i> kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type <i>RAS</i> . American Journal of Hematology, 2014, 89, 499-504.	2.0	30
454	Impact of comorbidities by ACE27 in the revised IPSS for patients with myelodysplastic syndromes. American Journal of Hematology, 2014, 89, 509-516.	2.0	30
455	Outcomes in RBC transfusion-dependent patients with low-intermediate-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS004 study. European Journal of Haematology, 2014, 93, 429-438.	1.1	32
456	Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1859-65.	1.4	4
457	Lessons from the Atomic Bomb About Secondary MDS. Current Hematologic Malignancy Reports, 2014, 9, 407-411.	1.2	1
458	Dysplasia Features of Myelodysplastic Syndrome in Ethnically Chinese People. Acta Haematologica, 2014, 131, 126-132.	0.7	7
459	Genetic Stratification in Myeloid Diseases: From Risk Assessment to Clinical Decision Support Tool. Rambam Maimonides Medical Journal, 2014, 5, e0025.	0.4	1
460	Validation of the Revised International Prognostic Scoring System for Patients with Myelodysplastic Syndromes. Acta Haematologica, 2014, 131, 231-238.	0.7	15
461	Initially Lymphocytic Sweet's Syndrome in Male Patients with Myelodysplasia: A Distinguished Clinicopathological Entity? Case Report and Systematic Review of the Literature. Acta Haematologica, 2014, 132, 220-225.	0.7	10
462	Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). Current Hematologic Malignancy Reports, 2014, 9, 57-65.	1.2	11
463	Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Annals of Hematology, 2014, 93, 57-64.	0.8	16

#	ARTICLE	IF	CITATIONS
464	Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2014, 49, 1022-1028.	1.3	7
465	Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current Practice. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 301-310.	1.2	2
466	Significance of telomere capture in myelodysplastic syndromes. <i>Medical Oncology</i> , 2014, 31, 216.	1.2	0
467	The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2014, 7, 61.	6.9	40
468	Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1130-1138.	2.0	9
469	A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 401-410.	0.2	51
470	Predicting response to epigenetic therapy. <i>Journal of Clinical Investigation</i> , 2014, 124, 47-55.	3.9	78
471	The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. <i>Haematologica</i> , 2014, 99, e31-e32.	1.7	34
472	Five-aza-2-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells. <i>Scientific Reports</i> , 2015, 5, 16709.	1.6	20
473	The Level of Bone Marrow WT1 Message is a Useful Marker to Differentiate Myelodysplastic Syndromes with Low Blast Percentage from Cytopenia due to Other Reasons. <i>Internal Medicine</i> , 2015, 54, 445-451.	0.3	5
474	IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015035.	0.5	22
475	REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015018.	0.5	7
476	Radiotherapy- and Chemotherapy-Induced Myelodysplasia Syndrome. <i>Medicine (United States)</i> , 2015, 94, e737.	0.4	19
477	Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. <i>Cancer Science</i> , 2015, 106, 287-293.	1.7	31
478	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 400-408.	1.7	50
479	Clonal origin and evolution of myelodysplastic syndrome analyzed by dysplastic morphology and fluorescence in situ hybridization. <i>International Journal of Hematology</i> , 2015, 101, 58-66.	0.7	1
480	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 12-15.	1.0	1
481	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. <i>Blood</i> , 2015, 126, 233-241.	0.6	361

#	ARTICLE	IF	CITATIONS
482	Chronic myelomonocytic leukemia: Forefront of the field in 2015. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 222-242.	2.0	22
483	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> , 2015, 126, 9-16.	0.6	1,493
484	Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. <i>Experimental Hematology and Oncology</i> , 2015, 4, 14.	2.0	32
485	The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 252-258.	0.7	5
486	Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, e177-e181.	1.7	10
487	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2016, 11, e0166245.	1.1	6
488	Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing. <i>Oncotarget</i> , 2016, 7, 32065-32078.	0.8	28
489	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	0.8	61
490	Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. <i>Leukemia</i> , 2016, 30, 2055-2063.	3.3	99
491	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. <i>Blood</i> , 2016, 127, 2890-2902.	0.6	96
492	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. <i>Modern Pathology</i> , 2016, 29, 1541-1551.	2.9	11
493	Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2016, 175, 393-401.	1.2	24
494	Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms. <i>International Journal of Hematology</i> , 2016, 104, 566-573.	0.7	14
495	Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki. <i>Cancer Science</i> , 2016, 107, 1484-1491.	1.7	9
496	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. <i>Journal of Hematology and Oncology</i> , 2016, 9, 39.	6.9	36
497	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. <i>Haematologica</i> , 2016, 101, e224-e227.	1.7	36
498	Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. <i>Current Oncology Reports</i> , 2016, 18, 4.	1.8	17
499	Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2016, 103, 227-233.	0.7	3

#	ARTICLE	IF	CITATIONS
500	Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 154, 9-23.	1.1	139
501	The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system. <i>Leukemia</i> , 2016, 30, 658-665.	3.3	40
502	Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 865-71.	1.4	9
503	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2017, 92, 674-682.	2.0	24
504	Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. <i>International Journal of Hematology</i> , 2017, 106, 375-384.	0.7	17
505	<i>GPX3</i> methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome. <i>Cancer Medicine</i> , 2017, 6, 267-274.	1.3	22
506	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 50 chronic myelomonocytic leukemia. <i>Modern Pathology</i> , 2017, 30, 1213-1222.	2.9	52
507	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 599-606.	2.0	38
508	Models of Prognostication in Chronic Myelomonocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 513-521.	1.2	9
509	Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 448-454.	1.2	4
510	Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). <i>Journal of Hematology and Oncology</i> , 2017, 10, 131.	6.9	8
511	Diagnostics and Prognostication of Myelodysplastic Syndromes. <i>Annals of Laboratory Medicine</i> , 2017, 37, 465-474.	1.2	18
512	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	0.8	153
513	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. <i>Blood Cancer Journal</i> , 2018, 8, 39.	2.8	68
514	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. <i>Clinical Epigenetics</i> , 2018, 10, 42.	1.8	36
515	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. <i>Annals of Hematology</i> , 2018, 97, 1183-1191.	0.8	12
516	NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. <i>Clinical Cancer Research</i> , 2018, 24, 1019-1029.	3.2	87
517	Intragenic hypomethylation of <i>DNMT3A</i> in patients with myelodysplastic syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 485-491.	1.4	5

#	ARTICLE	IF	CITATIONS
518	Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. <i>Clinical Cancer Research</i> , 2018, 24, 521-531.	3.2	64
519	DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. <i>Epigenetics</i> , 2018, 13, 8-18.	1.3	14
520	Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. <i>Oncologist</i> , 2018, 23, 159-170.	1.9	27
521	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2018, 103, 69-79.	1.7	35
522	Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3987.	1.8	13
523	Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. <i>Blood</i> , 2018, 132, 2629-2638.	0.6	71
524	Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 467-476.	1.2	4
525	Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or Tj ETQq1 1 0.784314 rgBT /Overl... 2018, 109, 3209-3215.	1.7	15
526	Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2018, 93, 824-840.	2.0	101
527	Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment. <i>Frontiers in Oncology</i> , 2018, 8, 119.	1.3	10
528	Minimally invasive mitral valve repair via right mini-thoracotomy in patient with myelodysplastic syndrome. <i>Journal of Cardiothoracic Surgery</i> , 2018, 13, 45.	0.4	0
529	More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. <i>BMC Hematology</i> , 2018, 18, 4.	2.6	8
530	Part 2: Myelodysplastic syndromes " classification systems. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 262-266.	0.1	3
531	ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. <i>Pathobiology</i> , 2019, 86, 30-38.	1.9	71
532	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 410-418.	1.0	18
533	Immune Dysregulation in MDS: The Role of Cytokines and Immune Cells. , 2019, , .		2
534	Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2019, 110, 533-542.	0.7	6
535	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. , 0, , .		0

#	ARTICLE	IF	CITATIONS
536	A novel automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA. <i>Scientific Reports</i> , 2019, 9, 13385.	1.6	51
537	Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma. <i>Cells</i> , 2019, 8, 103.	1.8	37
538	Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine. <i>Cancer Medicine</i> , 2019, 8, 2188-2195.	1.3	8
539	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	1.7	93
540	Diagnosis and Classification of Myelodysplastic Syndrome. , 0, , .		3
541	Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 543-549.	1.2	2
542	Hypomethylation of MIR-378 5a flanking region predicts poor survival in young patients with myelodysplastic syndrome. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1067.	0.6	2
543	Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia. <i>British Journal of Haematology</i> , 2020, 188, 796-800.	1.2	4
544	No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki. <i>Cancer Science</i> , 2020, 111, 4490-4499.	1.7	3
545	Serum Inflamm-miR Signature: A Biomarker of Myelodysplastic Syndrome?. <i>Frontiers in Oncology</i> , 2020, 10, 595838.	1.3	1
546	Prognostic Markers of Myelodysplastic Syndromes. <i>Medicina (Lithuania)</i> , 2020, 56, 376.	0.8	10
547	Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2020, 112, 825-834.	0.7	2
548	TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis. <i>Cell Reports</i> , 2020, 30, 2776-2790.e6.	2.9	27
549	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3025.	1.8	11
550	The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3033.	1.8	3
551	The Blood Circulating Rare Cell Population. What Is It and What Is It Good for?. <i>Cells</i> , 2020, 9, 790.	1.8	23
552	Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2021, 100, 63-78.	0.8	3
553	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS. <i>Leukemia</i> , 2021, 35, 835-849.	3.3	54

#	ARTICLE	IF	CITATIONS
554	Pre-transplantation cyto-reduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. <i>Cancer Communications</i> , 2021, 41, 333-344.	3.7	5
555	DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. <i>Genome Research</i> , 2021, 31, 747-761.	2.4	20
556	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 3176-3187.	3.3	8
557	Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization for detecting chromosome abnormalities in myelodysplastic syndromes. <i>Medicine (United States)</i> , 2021, 100, e25768.	0.4	1
559	Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes. <i>BMC Cancer</i> , 2021, 21, 546.	1.1	6
560	Micromegakaryocytes in peripheral blood in a case of AML, t(6;11)(q27;23). <i>BMJ Case Reports</i> , 2021, 14, e235176.	0.2	1
561	Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. <i>European Journal of Haematology</i> , 2021, 107, 265-274.	1.1	10
562	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. <i>Blood</i> , 2022, 139, 323-332.	0.6	80
563	Programmed necroptosis is upregulated in low-grade myelodysplastic syndromes and may play a role in the pathogenesis. <i>Experimental Hematology</i> , 2021, 103, 60-72.e5.	0.2	4
564	Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 751668.	1.3	2
565	Cytogenetic findings in 179 patients with myelodysplastic syndromes. <i>Annals of Hematology</i> , 1995, 70, 171-187.	0.8	5
566	Synthesis of a novel cytokine and its gene (LD78) expressions in hematopoietic fresh tumor cells and cell lines.. <i>Journal of Clinical Investigation</i> , 1989, 84, 1707-1712.	3.9	49
567	Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells.. <i>Journal of Clinical Investigation</i> , 1991, 88, 223-230.	3.9	51
568	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. <i>Journal of Clinical Investigation</i> , 2015, 125, 1857-1872.	3.9	151
569	Myelodysplastic Syndromes: Recent Progress in Diagnosis and Understanding of Their Pathophysiology. <i>Journal of Nippon Medical School</i> , 2006, 73, 300-307.	0.3	11
570	The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts. <i>PLoS ONE</i> , 2008, 3, e1970.	1.1	113
571	EZH2 Mutations Are Related to Low Blast Percentage in Bone Marrow and -7/del(7q) in De Novo Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2013, 8, e61341.	1.1	53
572	Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e100206.	1.1	47

#	ARTICLE	IF	CITATIONS
573	Vasculitis in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: A Report of Two Cases. <i>Journal of Hematology</i> (Brossard, Quebec), 2018, 7, 158-162.	0.4	3
574	Standards and impact of hematopathology in myelodysplastic syndromes (MDS). <i>Oncotarget</i> , 2010, 1, 483-96.	0.8	28
575	Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. <i>Oncotarget</i> , 2017, 8, 103274-103282.	0.8	12
576	Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase. <i>Oncotarget</i> , 2012, 3, 1158-1168.	0.8	19
577	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. <i>Oncotarget</i> , 2016, 7, 14172-14187.	0.8	86
578	Azacitidine (Vidaza [®]) in the treatment of myelodysplastic syndromes. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 377-388.	0.9	79
579	Myelodysplastic syndromes: moving towards personalized management. <i>Haematologica</i> , 2020, 105, 1765-1779.	1.7	52
580	Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9562.	1.2	3
582	A Case of Intestinal Behcet Disease and Myelodysplastic Syndrome Complicated by Fournier's Gangrene. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2006, 59, 385-389.	0.1	1
583	A CASE OF AORTIC VALVE REPLACEMENT IN A PATIENT WITH MYELODYSPLASTIC SYNDROME AND AORTIC VALVE STENOSIS. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2010, 71, 2825-2829.	0.0	1
584	Prediction of Progression from Refractory Cytopenia with Unilineage Dysplasia by Analysis of Bone Marrow Blast Cell Composition. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2012, 52, 63-66.	0.3	4
585	Localization of Lysozyme in Normal Human Blood Cells: An Ultrastructural Immunogold Study. <i>Journal of the Japan Society of the Reticuloendothelial System</i> , 1987, 27, 307-315.	0.0	1
586	Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems. <i>Turkish Journal of Haematology</i> , 2016, 33, 119-126.	0.2	4
587	Diagnostic Problems In Chronic Basophilic Leukemia. <i>Turkish Journal of Haematology</i> , 2018, 35, 283-289.	0.2	4
588	Influence of Prognostic Factors on Overall Survival in Myelodysplastic Syndromes. <i>Materia Socio-medica</i> , 2014, 26, 292.	0.3	6
589	Title is missing!. <i>Acta Hepatologica Japonica</i> , 2000, 41, 823-828.	0.0	4
590	Myelodysplasia and Acute Leukemia Following High-Dose Chemotherapy. , 2000, , 261-277.		0
591	A Case of Acute Feline Monocytic Leukemia. <i>Nippon Juishikai Zasshi Journal of the Japan Veterinary Medical Association</i> , 2002, 55, 596-600.	0.0	0

#	ARTICLE	IF	CITATIONS
592	Rheumatoid Arthritis Preceded by Interstitial Pneumonia Associated with Myelodysplastic Syndrome: A Case Report. Kitakanto Medical Journal, 2003, 53, 289-291.	0.0	0
593	AnÃmien. , 2003, , 1013-1027.		2
594	The New WHO Classification for Akute Myeloid Leukemias and Myelodysplastic Syndromes. Hamatologie Und Bluttransfusion, 2003, , 3-6.	0.0	0
595	A Case of Transverse Colon Cancer with Myelodysplastic Syndrome. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2003, 28, 765-770.	0.0	1
596	Myelodysplastic Syndrome Developing into Myeloid Leukemia in a Cat Following Treatment for Lymphoma. Nippon Juishikai Zasshi Journal of the Japan Veterinary Medical Association, 2005, 58, 825-828.	0.0	0
597	çŠ-ã*çE«ã®é€è;€ã™™è...«ç~; Nippon Juishikai Zasshi Journal of the Japan Veterinary Medical Association, 2005, 58, 434-435.	0.0	0
598	Molecular Biology of Myelodysplasia. , 2006, , 23-38.		0
600	Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. F1000 Medicine Reports, 2009, 1, .	2.9	0
601	Molecularly Targeted Therapies in Pediatric Myelodysplastic Syndromes. , 2010, , 155-176.		0
602	Mast Cell Infiltration is Associated with Myelofibrosis and Angiogenesis in Myelodysplastic Syndromes. The Showa University Journal of Medical Sciences, 2010, 22, 51-61.	0.1	0
603	A Case Of Anemia and Thrombocytopenia with Myelodysplastic Syndrome Successfully Treated with Juzentaihoto and Malt Sugar. Kampo Medicine, 2011, 62, 363-368.	0.1	2
605	The History of the Myelodysplastic Syndromes. , 2011, , 1-4.		1
606	A case of synchronous double cancer of the stomach and the ascending colon associated with myelodysplastic syndrome. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2012, 73, 502-508.	0.0	2
607	PTK2 and PTPN11 expression in myelodysplastic syndromes. Clinics, 2013, 68, 1371-1375.	0.6	0
608	Evaluation of the FAB classification of acute leukemia with special reference to differential diagnosis between acute lymphoblastic leukemia cells and acute myeloid leukemia cells.. The Journal of the Japanese Society of Clinical Cytology, 1986, 25, 1003-1009.	0.0	0
609	REVIEW : ESSENTIAL THROMBOCYTHEMIA. The KITAKANTO Medical Journal, 1987, 37, 571-574.	0.0	0
610	Cytobiology and Clinical Findings of Myelodysplastic Syndromes. Recent Results in Cancer Research, 1988, 106, 172-179.	1.8	1
611	Role of Free Radical Reactions in Myelodysplastic Syndrome. Journal of Clinical Biochemistry and Nutrition, 1988, 5, 75-79.	0.6	0

#	ARTICLE	IF	CITATIONS
613	A case of rheumatoid arthritis complicated with secondary amyloidosis and myelodysplastic syndrome.. Japanese Journal of Clinical Immunology, 1989, 12, 415-421.	0.0	0
614	A CASE OF MYELODYSPLASTIC SYNDROME WITH SEPTIC SHOCK CAUSED BY GAS-PRODUCING ESCHERICHIA COLI. The KITAKANTO Medical Journal, 1989, 39, 539-542.	0.0	0
615	A patient with RAEB showing initial symptoms in the oral cavity.. Nihon Koku Geka Gakkai Zasshi, 1990, 36, 138-142.	0.0	0
616	Effects of Hematopoietic Growth Factors on Myelodysplastic Syndrome Progenitors. , 1990, , 115-122.		0
617	Studies on hematopoietic progenitor cells in acute leukemia and related disease. Okayama Igakkai Zasshi, 1991, 103, 1159-1169.	0.0	0
618	Regulation of transferrin receptor (TfR) expression on erythroblasts from patients with myelodysplastic syndrome. Okayama Igakkai Zasshi, 1991, 103, 869-877.	0.0	0
619	Enzyme Cytochemical Studies in Myelodysplastic Syndromes. , 1992, , 51-59.		0
620	Myelodysplastic Syndrome Complicated by Malignant Lymphoma : Report of an Autopsy Case.. Journal of the Japan Society of the Reticuloendothelial System, 1992, 32, 119-127.	0.0	0
621	A case of myelodysplastic syndrome with oral manifestation.. Nihon Koku Geka Gakkai Zasshi, 1992, 38, 1453-1454.	0.0	0
622	A case of rheumatoid arthritis complicated with myelodysplastic syndrome.. Japanese Journal of Clinical Immunology, 1992, 15, 305-309.	0.0	0
623	Clinical studies on atypical leukemia. Okayama Igakkai Zasshi, 1993, 105, 427-436.	0.0	0
624	Superoxide anion ($O_2^{\cdot-}$) production by neutrophils in myelodysplastic syndrome (MDS). Okayama Igakkai Zasshi, 1993, 105, 919-932.	0.0	1
625	Hypoplastic leukemia. Okayama Igakkai Zasshi, 1994, 106, 93-102.	0.0	0
626	Diagnostic Criteria of Leukemias in Domestic Animals. Nippon Juishikai Zasshi Journal of the Japan Veterinary Medical Association, 1994, 47, 1-8.	0.0	0
627	Low dose melphalan for myelodysplastic syndrome. Okayama Igakkai Zasshi, 1994, 106, 947-962.	0.0	0
628	Cell cycle in myelodysplastic syndrome. Okayama Igakkai Zasshi, 1994, 106, 861-874.	0.0	0
629	Sideroblastogram in patients with myelodysplastic syndrome. Okayama Igakkai Zasshi, 1994, 106, 893-906.	0.0	0
630	Sweet's disease.. Japanese Journal of Clinical Immunology, 1996, 19, 169-178.	0.0	1

#	ARTICLE	IF	CITATIONS
631	Three Cases of Myelodysplastic Syndrome. Importance of Microscopic Examination of Hemogram.. Journal of the Japanese Association of Rural Medicine, 1996, 45, 24-27.	0.0	0
633	A case of a maintenance-hemodialyzed elderly patient complicated with hypoplastic myelodysplastic syndrome(MDS).. Nihon Toseki Igakkai Zasshi, 1996, 29, 417-423.	0.2	0
634	Chronic Myelomonocytic Leukaemia. , 0, , .		1
635	A case of therapy-related myelodysplastic syndrome after chemoradiation for advanced tongue carcinoma. Journal of Japanese Society of Oral Oncology, 2019, 31, 91-96.	0.0	1
636	A Case of Myelodysplastic Syndrome Diagnosed after Colectomy for Colon Cancer with a Poor Prognosis. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2020, 81, 2297-2302.	0.0	0
639	Diagnosis and Classification of the Acute Myeloid Leukemias (with Discussion of the Role of the) Tj ETQq1 1 0.784314 rgBT /Overlock		1
640	Comparison of scoring systems in primary myelodysplastic syndromes. Annals of Hematology, 1995, 70, 301-308.	0.8	0
641	FAB classification of myelodysplastic syndromes: merits and controversies. Annals of Hematology, 1995, 71, 3-11.	0.8	0
642	Myelodysplastic syndromes. Western Journal of Medicine, 1989, 151, 161-7.	0.3	20
643	An appraisal of bone marrow biopsy in assessment of sick dogs. Canadian Journal of Comparative Medicine Revue Canadienne De MÃ©decine ComparÃ©e, 1985, 49, 34-42.	0.3	1
644	Dysmyelopoiesis in the cat: a hematological disorder resembling refractory anemia with excess blasts in man. Canadian Journal of Veterinary Research, 1986, 50, 3-6.	1.1	30
645	Haematological improvement with conservative management in an infant with myelodysplasia. Journal of the Royal Society of Medicine, 1992, 85, 495-6.	1.1	0
646	Treatment of chronic myelomonocytic leukemia. Vincristine and prednisone therapy during symptomatic phase or after transformation to acute leukemia. Western Journal of Medicine, 1985, 143, 524-7.	0.3	2
647	Granulocyte Fc-IgG and C3b receptor expression in the primary myelodysplastic syndromes (MDS): relationship with dysgranulopoiesis and evidence for heterogeneity of morphological subgroups. Clinical and Experimental Immunology, 1984, 55, 183-8.	1.1	4
648	Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood. MedGenMed: Medscape General Medicine, 2005, 7, 21.	0.2	3
649	p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. American Journal of Pathology, 1994, 145, 338-44.	1.9	36
650	Transformation of cytogenetically normal chronic myelomonocytic leukaemia to an acute myeloid leukaemia and the emergence of a novel +13, +15 double trisomy resulting in an adverse outcome. Ulster Medical Journal, 2007, 76, 131-5.	0.2	0
651	Decitabine in the treatment of myelodysplastic syndromes. Therapeutics and Clinical Risk Management, 2007, 3, 807-17.	0.9	76

#	ARTICLE	IF	CITATIONS
652	Antineutrophil cytoplasmic antibodies in myelodysplasia. <i>Ulster Medical Journal</i> , 1996, 65, 55-7.	0.2	3
653	The myelodysplastic syndromes. <i>Journal of the National Medical Association</i> , 1987, 79, 781-4.	0.6	0
654	New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?. <i>Blood Transfusion</i> , 2008, 6, 191-8.	0.3	6
655	Management of myelodysplastic syndromes: 2008 update. <i>Oncology</i> , 2008, 22, 1344-52.	0.4	6
656	Nonarteritic anterior ischemic optic neuropathy associated with chronic anemia: a case series of myelodysplastic syndrome patients. <i>Clinical Ophthalmology</i> , 2009, 3, 133-7.	0.9	7
657	Gene expression patterns in myelodysplasia underline the role of apoptosis and differentiation in disease initiation and progression. <i>Translational Oncogenomics</i> , 2008, 3, 137-49.	1.7	13
658	Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. <i>Clinics</i> , 2011, 66, 793-9.	0.6	3
659	Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. <i>American Journal of Cancer Research</i> , 2011, 1, 531-41.	1.4	11
660	Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. <i>Indian Journal of Medical Research</i> , 2011, 134, 452-7.	0.4	15
662	Myelodysplastic syndromes in children: where are we today?. <i>Ochsner Journal</i> , 2012, 12, 216-20.	0.5	7
664	Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2013, 7, 30-4.	0.3	0
665	A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2014, 26, E1-4.	0.7	1
667	Myelodysplastic Syndrome with 6q Deletion as the Sole Chromosome Abnormality in an Iranian Patient: A Case Report with Review of Literature. <i>Iranian Journal of Public Health</i> , 2013, 42, 1187-91.	0.3	0
668	Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2013, 23, 109-16.	0.7	1
669	Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 707-717.	0.2	1
670	Impact of gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. <i>American Journal of Cancer Research</i> , 2021, 11, 955-967.	1.4	0
671	Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview. <i>Frontiers in Oncology</i> , 2021, 11, 778741.	1.3	3
672	A Rare Case of Ankylosing Spondylitis Coexisting with Relapsing Polychondritis, Antiphospholipid Syndrome, and Myelodysplastic Syndrome. <i>Internal Medicine</i> , 2022, , .	0.3	0

#	ARTICLE	IF	CITATIONS
673	Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1989, 6, 199-205.	1.0	6
674	Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. <i>American Journal of Hematology</i> , 2022, 97, 514-518.	2.0	30
675	A Case of Untreated Myeloid Sarcoma of the Pancreas Head Region: Diagnostic Process of AML Subtyping in an Autoptic Case. <i>Case Reports in Pathology</i> , 2021, 2021, 1-7.	0.2	1
676	Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 1995, 71, 293-299.	0.8	2
677	The iatrogenic leukaemias induced by radio-and/or chemotherapy. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1987, 4, 245-257.	1.0	7
678	Evolution of multiple cytogenetic clones and leukemic transformation in a case of myelodysplastic syndrome. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1989, 6, 233-238.	1.0	2
679	Different distribution of DNA polymerases β and δ in bone marrow and peripheral blood from human leukemia. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1988, 5, 181-186.	1.0	1
683	Somatic mutations in SF3B1 aberrant-negative MDSs most commonly involved in TP53 genes. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 3586-3589.	1.6	0
684	ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: WJHS MDS01 trial. <i>International Journal of Hematology</i> , 0, , .	0.7	0
685	Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia. <i>Wiener Medizinische Wochenschrift</i> , 0, , .	0.5	1
686	Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia. <i>Wiener Medizinische Wochenschrift</i> , 0, , .	0.5	0
687	Significance of reduced renal function in patients with chronic myelomonocytic leukemia. <i>Wiener Medizinische Wochenschrift</i> , 2023, 173, 3-8.	0.5	1
690	Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia. <i>Wiener Medizinische Wochenschrift</i> , 0, , .	0.5	0
691	Significance of C-reactive protein in patients with chronic myelomonocytic leukemia. <i>Wiener Medizinische Wochenschrift</i> , 2023, 173, 15-20.	0.5	1
692	Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia. <i>Wiener Medizinische Wochenschrift</i> , 0, , .	0.5	0